Mylan's Acquisition of Matrix

According to analysts, the deal was a winning proposition for both the parties to the transaction. Where Mylan was concerned, Matrix's takeover helped it to enter the global generic markets beyond the US market.

In particular, this acquisition helped Mylan to enter the emerging pharmaceutical markets of India, China, and South Africa, given Matrix's presence in these regions. Second, the deal would also aid Mylan enter the high-margin European markets through Matrix's subsidiary Docpharma NV⁹ (Docpharma), which was already operating in the European markets.

Jim Miller, president of PharmSource Information Services, Inc.¹⁰, noted, "What is most striking about the deal is that although Mylan is the buyer, Matrix is clearly the more sophisticated global player. Matrix has built a sophisticated supply chain that sources early-stage intermediates in China, converts them to APIs in FDA-approved plants in India, formulates the APIs into finished dosage forms, and sells them in Asian and European markets. Mylan, by contrast, manufactures only drug products and operates largely in the United States. Matrix's global capabilities are likely to have much greater value to Mylan in the generics and branded generics markets than they are in contract manufacturing."¹¹ , ¹²...